SEARCH

SEARCH BY CITATION

References

  • Albers D. S. and Sonsalla P. K. (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275, 11041114.
  • Ali S. F., Newport R. R., Holson W., Slikker Jr W. and Bowyer J. F. (1995) Low environmental temperatures or pharmacologic agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice. Ann. NY Acad. Sci. 765, 338.
    Direct Link:
  • Ali S. F., Newport G. D. and Slikker Jr W. (1996) Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents. Ann. NY Acad. Sci. 801, 187198.
  • Ali S. F., Imam S. Z. and Itzhak Y. (2005) Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and neuroprotection by antioxidants and selective NOS inhibitors. Ann. NY Acad. Sci. 1053, 9798.
  • Aschner M. (1998) Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology 19, 269281.
  • Aschner M., Allen J. W., Kimelberg H. K., LoPachin R. M. and Streit W. J. (1999) Glial cells in neurotoxicity development. Annu. Rev. Pharmacol. Toxicol. 39, 151173.
  • Axt K. J., Commins D. L., Vosmer G. and Seiden L. S. (1990) alpha-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res. 515, 269276.
  • Block M. L. and Hong J. S. (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 7798.
  • Bowyer J. F., Davies D. L., Schmued L., Broening H. W., Newport G. D., Slikker Jr W. and Holson R. R. (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Therapeut. 268, 15711580.
  • Cadet J. L., Ali S. and Epstein C. (1994) Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann. NY Acad. Sci. 738, 388391.
  • Cappon G. D., Broening H. W., Pu C., Morford L. and Vorhees C. V. (1996) Alpha-phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia. Synapse (New York, NY) 24, 173181.
  • Cardozo D. L. (1993) Midbrain dopaminergic neurons from postnatal rat in long-term primary culture. Neuroscience 56, 409421.
  • Caudle W. M., Richardson J. R., Delea K. C., Guillot T. S., Wang M., Pennell K. D. and Miller G. W. (2006) Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson’s disease-associated dopamine toxicity. Toxicol. Sci. 92, 490499.
  • Caudle W. M., Richardson J. R., Wang M. Z., Taylor T. N., Guillot T. S., McCormack A. L., Colebrooke R. E., Di Monte D. A., Emson P. C. and Miller G. W. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 81388148.
  • Colebrooke R. E., Chan P. M., Lynch P. J., Mooslehner K. and Emson P. C. (2007) Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene. Brain Res. 1152, 1016.
  • Cubells J. F., Rayport S., Rajendran G. and Sulzer D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14, 22602271.
  • Donovan D. M., Miner L. L., Perry M. P. et al. (1999) Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res. Mol. Brain Res. 73, 3749.
  • Eiden L. E. (2000) The vesicular neurotransmitter transporters: current perspectives and future prospects. FASEB J. 14, 23962400.
  • Escubedo E., Guitart L., Sureda F. X., Jimenez A., Pubill D., Pallas M., Camins A. and Camarasa J. (1998) Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 814, 120126.
  • Eyerman D. J. and Yamamoto B. K. (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J. Neurochem. 103, 12191227.
  • Flora G., Lee Y. W., Nath A., Maragos W., Hennig B. and Toborek M. (2002) Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromol. Med. 2, 7185.
  • Fon E. A., Pothos E. N., Sun B. C., Killeen N., Sulzer D. and Edwards R. H. (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 12711283.
  • Fumagalli F., Gainetdinov R. R., Valenzano K. J. and Caron M. G. (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18, 48614869.
  • Fumagalli F., Gainetdinov R. R., Wang Y. M., Valenzano K. J., Miller G. W. and Caron M. G. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19, 24242431.
  • Gainetdinov R. R., Fumagalli F., Jones S. R. and Caron M. G. (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 13221325.
  • Gainetdinov R. R., Fumagalli F., Wang Y. M., Jones S. R., Levey A. I., Miller G. W. and Caron M. G. (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70, 19731978.
  • Gao H. M., Liu B., Zhang W. and Hong J. S. (2003) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. FASEB J. 17, 19571959.
  • Gasnier B. (2000) The loading of neurotransmitters into synaptic vesicles. Biochimie 82, 327337.
  • Giovanni A., Liang L. P., Hastings T. G. and Zigmond M. J. (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64, 18191825.
  • Gluck M. R., Moy L. Y., Jayatilleke E., Hogan K. A., Manzino L. and Sonsalla P. K. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152160.
  • Guilarte T. R., Nihei M. K., McGlothan J. L. and Howard A. S. (2003) Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122, 499513.
  • Guillot T. S., Richardson J. R., Wang M. Z., Li Y. J., Taylor T. N., Ciliax B. J., Zachrisson O., Mercer A. and Miller G. W. (2008) PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides (in press).
  • Hatcher J. M., Richardson J. R., Guillot T. S., McCormack A. L., Di Monte D. A., Jones D. P., Pennell K. D. and Miller G. W. (2007) Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp. Neurol. 204, 619630.
  • Hess A., Desiderio C. and McAuliffe W. G. (1990) Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies. J. Neurocytol. 19, 338342.
  • Ito M., Numachi Y., Ohara A. and Sora I. (2008) Hyperthermic and lethal effects of methamphetamine: Roles of dopamine D1 and D2 receptors. Neurosci. Lett. 438, 327329.
  • Johnson-Davis K. L., Truong J. G., Fleckenstein A. E. and Wilkins D. G. (2004) Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Therapeut. 309, 578586.
  • Katsuyama M., Kato T., Karai N., Nakamura M. and Katsube J. (1986) Reversal by L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), a L-norepinephrine precursor of reserpine- or tetrabenazine-induced hypothermia. Arch. Int. Pharmacodyn. Ther. 283, 6170.
  • Ladenheim B., Krasnova I. N., Deng X., Oyler J. M., Polettini A., Moran T. H., Huestis M. A. and Cadet J. L. (2000) Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol. Pharmacol. 58, 12471256.
  • Larsen K. E., Fon E. A., Hastings T. G., Edwards R. H. and Sulzer D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22, 89518960.
  • LaVoie M. J. and Hastings T. G. (1999a) Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J. Neurochem. 73, 25462554.
  • LaVoie M. J. and Hastings T. G. (1999b) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19, 14841491.
  • LaVoie M. J., Card J. P. and Hastings T. G. (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 187, 4757.
  • Metzger R. R., Haughey H. M., Wilkins D. G., Gibb J. W., Hanson G. R. and Fleckenstein A. E. (2000) Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J. Pharmacol. Exp. Therapeut. 295, 10771085.
  • Miller D. B. and O’Callaghan J. P. (1994) Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Therapeut. 270, 752760.
  • Miller D. B., Blackman C. F. and O’Callaghan J. P. (1987) An increase in glial fibrillary acidic protein follows brain hyperthermia in rats. Brain Res. 415, 371374.
  • Miller G. W., Gainetdinov R. R., Levey A. I. and Caron M. G. (1999) Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20, 424429.
  • Miyazaki I., Asanuma M., Diaz-Corrales F. J., Fukuda M., Kitaichi K., Miyoshi K. and Ogawa N. (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J. 20, 571573.
  • Mooslehner K. A., Chan P. M., Xu W., Liu L., Smadja C., Humby T., Allen N. D., Wilkinson L. S. and Emson P. C. (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 21, 53215331.
  • Mosharov E. V., Gong L. W., Khanna B., Sulzer D. and Lindau M. (2003) Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J. Neurosci. 23, 58355845.
  • Numachi Y., Ohara A., Yamashita M. et al. (2007) Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur. J. Pharmacol. 572, 120128.
  • O’Callaghan J. P. and Miller D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Therapeut. 270, 741751.
  • O’Callaghan J. P. and Miller D. B. (2002) Neurotoxic effects of substituted amphetamines in rats and mice, in Handbook of Neurotoxicology, Vol. 2 (MassaroE. J., ed.), pp. 269301. Humana Press, Totowa, NJ.
  • O’Callaghan J. P., Jensen K. F. and Miller D. B. (1995) Quantitative aspects of drug and toxicant-induced astrogliosis. Neurochem. Int. 26, 115124.
  • O’Callaghan J. P., Imai H., Miller D. B. and Minter A. (1999) Quantitative immunoblots of proteins resolved from brain homogenates: underestimation of specific protein concentration and of treatment effects. Anal. Biochem. 274, 1826.
  • Patel J., Mooslehner K. A., Chan P. M., Emson P. C. and Stamford J. A. (2003) Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J. Neurochem. 85, 898910.
  • Payne J., Maher F., Simpson I., Mattice L. and Davies P. (1997) Glucose transporter Glut 5 expression in microglial cells. Glia 21, 327331.
  • Pothos E. N., Larsen K. E., Krantz D. E., Liu Y., Haycock J. W., Setlik W., Gershon M. D., Edwards R. H. and Sulzer D. (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20, 72977306.
  • Radad K., Gille G. and Rausch W. D. (2008) Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicol. In Vitro 22, 6874.
  • Ricaurte G. A., Schuster C. R. and Seiden L. S. (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193, 153163.
  • Ricaurte G. A., Guillery R. W., Seiden L. S., Schuster C. R. and Moore R. Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235, 93103.
  • Ricaurte G. A., Seiden L. S. and Schuster C. R. (1983) Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine. Neuropharmacology 22, 13831388.
  • Richardson J. R., Caudle W. M., Wang M., Dean E. D., Pennell K. D. and Miller G. W. (2006) Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson’s disease. FASEB J. 20, 16951697.
  • Richardson J. R., Caudle W. M., Guillot T. S. et al. (2007) Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol. Sci. 95, 196204.
  • Riddle E. L., Topham M. K., Haycock J. W., Hanson G. R. and Fleckenstein A. E. (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449, 7174.
  • Seiden L. S. (1985) Methamphetamine: toxicity to dopaminergic neurons. NIDA Res. Monogr. 62, 100116.
  • Shaw G. G. (1971) Hypothermia produced in mice by histamine acting on the central nervous system. Br. J. Pharmacol. 42, 205214.
  • Sheng P., Cerruti C. and Cadet J. L. (1994) Methamphetamine (METH) causes reactive gliosis in vitro: attenuation by the ADP-ribosylation (ADPR) inhibitor, benzamide. Life Sci. 55, PL51PL54.
  • Smeyne M. and Smeyne R. J. (2002) Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson’s disease. Brain Res. Brain Res. Protocol. 9, 105111.
  • Sulzer D. and Pothos E. N. (2000) Regulation of quantal size by presynaptic mechanisms. Rev. Neurosci. 11, 159212.
  • Sulzer D. and Zecca L. (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotoxicity Res. 1, 181195.
  • Sulzer D., Pothos E., Sung H. M., Maidment N. T., Hoebel B. G. and Rayport S. (1992) Weak base model of amphetamine action. Ann. NY Acad. Sci. 654, 525528.
  • Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S. and Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 41024108.
  • Sulzer D., Sonders M. S., Poulsen N. W. and Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406433.
  • Takahashi N., Miner L. L., Sora I., Ujike H., Revay R. S., Kostic V., Jackson-Lewis V., Przedborski S. and Uhl G. R. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA 94, 99389943.
  • Thomas D. M., Walker P. D., Benjamins J. A., Geddes T. J. and Kuhn D. M. (2004a) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Therapeut. 311, 17.
  • Thomas D. M., Dowgiert J., Geddes T. J., Francescutti-Verbeem D., Liu X. and Kuhn D. M. (2004b) Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367, 349354.
  • Thomas D. M., Francescutti-Verbeem D. M. and Kuhn D. M. (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 105, 605616.
  • Ugarte Y. V., Rau K. S., Riddle E. L., Hanson G. R. and Fleckenstein A. E. (2003) Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors. Eur. J. Pharmacol. 472, 165171.
  • Vannucci S. J., Maher F. and Simpson I. A. (1997) Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21, 221.
  • Vergo S., Johansen J. L., Leist M. and Lotharius J. (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 1185, 1832.
  • Wagner G. C., Ricaurte G. A., Johanson C. E., Schuster C. R. and Seiden L. S. (1980a) Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology 30, 547550.
  • Wagner G. C., Ricaurte G. A., Seiden L. S., Schuster C. R., Miller R. J. and Westley J. (1980b) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151160.
  • Wagner G. C., Lucot J. B., Schuster C. R. and Seiden L. S. (1983) Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 270, 285288.
  • Wagner G. C., Carelli R. M. and Jarvis M. F. (1986) Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology 25, 559561.
  • Wilson J. M., Kalasinsky K. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W. and Kish S. J. (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2, 699703.
  • Yamamoto B. K. and Bankson M. G. (2005) Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 17, 87117.
  • Yamamoto B. K. and Zhu W. (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Therapeut. 287, 107114.